Pharmaceuticals

Increasing Cardiovascular Disease Cases Fueling Growth in the Blood Based Biomarkers Market

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Blood Based Biomarkers Market Over The Period 2026–2030?

The blood based biomarkers market has experienced rapid expansion in recent years. This market is projected to expand from $25.83 billion in 2025 to $28.94 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. The historical growth of this market can be linked to advances in molecular diagnostics, cancer screening programs, biomarker validation studies, hospital diagnostic infrastructure, and increased research funding.

The blood based biomarkers market is projected to experience swift expansion in the coming years. This market is anticipated to reach $45.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth during the projected period include the broadening use of liquid biopsy, advancements in AI-powered biomarker analytics, increasing demand for chronic disease monitoring, wider adoption of personalized medicine, and the proliferation of point-of-care testing. Key trends anticipated within the forecast timeframe encompass the rising embrace of non-invasive diagnostics, the wider application of precision oncology, greater utilization in early disease detection, an escalating need for personalized treatment monitoring, and the incorporation into clinical decision support systems.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

What Underlying Factors Are Accelerating The Growth Of The Blood Based Biomarkers Market?

The increasing incidence of cardiovascular diseases is anticipated to propel the expansion of the blood-based biomarkers market moving forward. These diseases encompass a range of heart and blood vessel disorders, including conditions such as coronary artery disease, heart failure, and stroke. The escalation in cardiovascular diseases is largely attributable to rising risk factors like inadequate diet and growing obesity rates. Blood-based biomarkers facilitate the diagnosis and monitoring of cardiovascular conditions by offering insights into disease progression, risk assessment, and treatment response through measurable substances within the blood. For instance, in September 2024, the National Center for Biotechnology Information, a US-based government agency, reported findings from a global health research initiative. Projections from this initiative indicated a 90% rise in cardiovascular disease prevalence between 2025 and 2050, with expected cardiovascular deaths reaching 35.6 million by 2050. Consequently, the escalating number of cardiovascular disease cases is driving the growth of blood-based biomarkers.

How Is The Blood Based Biomarkers Market Divided Into Its Major Segments?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

How Are Trends Transforming The Blood Based Biomarkers Market Landscape?

Leading companies in the blood-based biomarkers market are concentrating on technological breakthroughs, including high-accuracy blood biomarker tests, to facilitate physicians’ diagnosis of Alzheimer’s disease. A high-accuracy blood biomarker test serves as a diagnostic instrument that employs specific biomarkers within the blood to identify conditions or oversee health status with significant precision and trustworthiness. As an illustration, in October 2023, Quanterix, a life sciences company situated in the US, unveiled LucentAD p-Tau 217, a high-accuracy blood biomarker test created to support physicians in diagnosing Alzheimer’s disease (AD) among adults presenting with cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker closely associated with AD pathology, particularly the accumulation of amyloid in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, meeting strict diagnostic criteria, and is meant to be utilized alongside other diagnostic instruments rather than as an independent test.

Who Are The Prominent Organizations Shaping The Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Read the full blood based biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Region Is Projected To Dominate The Blood Based Biomarkers Market During The Forecast Period?

North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Blood Based Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2026, By The Business Research Company

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795